share_log

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K：重大事件
美股sec公告 ·  06/07 21:01
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. conducted its 2024 annual meeting of stockholders on June 3, 2024. During the meeting, two Class III directors were elected to serve until the 2027 annual meeting. The elected directors are Blake Borgeson, Ph.D., with 165,914,956 votes for and 26,093,759 withheld, and Dean Y. Li, M.D., Ph.D., with 166,211,058 votes for and 25,797,657 withheld. Additionally, an advisory resolution to approve executive compensation was passed with 188,317,831 votes for, 2,887,180 against, and 803,704 abstentions. The details of these proposals and their descriptions were previously filed with the SEC in the definitive Proxy Statement on April 23, 2024. The annual meeting's outcomes were reported in compliance with the SEC regulations.
Recursion Pharmaceuticals, Inc. conducted its 2024 annual meeting of stockholders on June 3, 2024. During the meeting, two Class III directors were elected to serve until the 2027 annual meeting. The elected directors are Blake Borgeson, Ph.D., with 165,914,956 votes for and 26,093,759 withheld, and Dean Y. Li, M.D., Ph.D., with 166,211,058 votes for and 25,797,657 withheld. Additionally, an advisory resolution to approve executive compensation was passed with 188,317,831 votes for, 2,887,180 against, and 803,704 abstentions. The details of these proposals and their descriptions were previously filed with the SEC in the definitive Proxy Statement on April 23, 2024. The annual meeting's outcomes were reported in compliance with the SEC regulations.
Recursion Pharmaceuticals, Inc.於2024年6月3日召開了2024年股東年會。在會議期間，選舉了兩名III類董事，任期至2027年年度股東大會。當選的董事是Blake Borgeson博士，獲得165,914,956票贊成和26,093,759票棄權，以及Dean Y. Li醫學博士和哲學博士，獲得166,211,058票贊成和25,797,657票棄權。另外，一項有關批准執行薪酬的諮詢決議獲得188,317,831票贊成，2,887,180票反對和803,704票棄權。這些建議和描述的細節早在2024年4月23日提交的代理聲明中已向SEC進行了申報。年度股東大會的結果符合SEC法規。
Recursion Pharmaceuticals, Inc.於2024年6月3日召開了2024年股東年會。在會議期間，選舉了兩名III類董事，任期至2027年年度股東大會。當選的董事是Blake Borgeson博士，獲得165,914,956票贊成和26,093,759票棄權，以及Dean Y. Li醫學博士和哲學博士，獲得166,211,058票贊成和25,797,657票棄權。另外，一項有關批准執行薪酬的諮詢決議獲得188,317,831票贊成，2,887,180票反對和803,704票棄權。這些建議和描述的細節早在2024年4月23日提交的代理聲明中已向SEC進行了申報。年度股東大會的結果符合SEC法規。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。